Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Commentary - Journal of Cancer Immunology & Therapy (2022) Volume 5, Issue 1

Most cancers prevention and screening: the subsequent step in the technology of precision medicinal drug.

Margaret Wynman*

Department of Oncology, King Abdullah Medical City, Makkah, Saudi Arabia

*Corresponding Author:
Margaret Wynman
Department of Oncology
King Abdullah Medical City
Makkah, Saudi Arabia

Received: 03-Feb-2022, Manuscript No. AAJCIT-22-105; Editor assigned: 05-Feb-2022, PreQC No. AAJCIT-22-105 (PQ); Reviewed: 18-Feb-2022, QC No AAJCIT-22-105; Revised: 21-Feb-2022, Manuscript No. AAJCIT-22-105 (R); Published: 28-Feb-2022, DOI:10.35841/aajcit- 6.1.105

Citation: Wynman M. Most cancers prevention and screening: The subsequent step in the technology of precision medicinal drug. J Cancer Immunol Ther. 2022; 6(1):105

Visit for more related articles at Journal of Cancer Immunology & Therapy


Decades of primary organic and clinical research have established that a protracted incubation time is needed for the development of malignant lesions. Even after publicity to recognized cancer causing agents, which include tobacco or human papilloma virus (HPV), cancers require enormous time to broaden. Consequently, there's adequate opportunity to detect early precancerous lesions and interfere for the duration of the initiation and promoting steps of the carcinogenic process, for that reason reversing or delaying the route of most cancers progression thru screening and prevention. The genomic revolution and technological advances are drivers in deciphering the molecular activities contributing to ailment development and making precision targeting in cancer screening and prevention inside the realm of application for gain of excessive-hazard individuals after which, optimistically, the overall populace.

The function of most cancers prevention and early detection

Most cancers is a main cause of dying. Every year, the wide variety of incident cancer instances keeps to boom globally. Through 2020, the range of incident most cancers cases identified yearly is expected to rise to fifteen million. Fortunately, several cancer sorts, especially colorectal, breast, and prostate cancer, can be detected by means of recurring screening which ends up in the early detection of malignant lesions [1]. Prevention is defined as “the protection of fitness with the aid of private and network-extensive efforts” [2]. Those efforts are performed through describing the burden of most cancers, figuring out its reasons, and comparing and imposing cancer prevention interventions. Historic perspectives of cancer prevention research have in general focused on decreasing incidence and most cancers-related mortality. Early efforts in most cancers prevention focused on both synthesized chemical compounds (e.g. retinoids, tamoxifen, and so forth.) and natural compounds (e.g. β-carotene, omega-three fish oil, etc.). Efforts have greater lately broadened to consist of interventions focused on ‘predisorder’ or the ones intended to delay carcinogenesis. [1]

Cancer hazard is stimulated with the aid of a aggregate of genetic and environmental factors, together with behavioral, lifestyle, and environmental exposures. A people’ chance is the sum of those various factors, although the effect magnitude of a single component is tough to quantify. In vitro and in vivo experimental evaluation has allowed for the identity of genes, along with FOXA2, PIK3CA, and RB1, that can force most cancers initiation and development [3]. This method becomes more complicated with the addition of recent genetic activities.

Several prevention and early detection mechanisms were recognized to aid in lowering cancer prevalence and are multilevel, related to number one, secondary, and tertiary processes. Number one most cancers prevention involves the direct avoidance or reduction in exposure to known carcinogenic elements. Key examples of number one prevention consist of tobacco cessation, modifications in food plan (e.g. reduced pork consumption, proscribing fatty meals) and extended bodily pastime. Number one prevention techniques contain modifying way of life factors that confer risk of developing most cancers (e.g., workout, tobacco cessation, and dietary supplements) and protective therapeutics (e.g. vaccination) which have tested long-term efficacy for cancer prevention. Secondary prevention allows stagnating, inhibiting, or reversing carcinogenesis. These techniques regularly involve the early detection, remedy, or removal of precancerous lesions. Tertiary prevention can be initiated after a diagnosis of most cancers to improve pleasant of lifestyles and survivorship [4]. It is important to word that the definitions of primary, secondary, and tertiary prevention can range, but the average message of prevention is the same.

Precision prevention

Purpose of most cancers prevention is to inhibit the formation of most cancers prior to initiation, number one prevention is crucial to accomplish this purpose. Precision prevention carries precision medication techniques and the people’ chance profile, which is described by means of genomic and way of life risk elements. The modern age of medical innovation has recognized several strategies that can be fortuitous, in the main in early detection of cancers and make the most genetic risk factors. The usability of cfDNA, ctDNA, and CTCs for the early detection of cancer has promise, yet there are several limitations to those techniques. The described techniques have little effectiveness in detecting premalignant or early degree sickness because of low systemic abundance of the marker and limitations in assay sensitivity and reproducibility [5].

The biomarker of interest won't be specific to tumor cells and produced by means of everyday or non-cancerous cells, may not be produced via early lesions, or may not be produced by way of all tumor cells. Moreover, as with any new technologies, implementation of these detection modalities is presently not possible on a large scale.


The aim of early detection and prevention of most cancers is to lessen, reverse or do away with ones’ danger of developing and loss of life of most cancers. To accomplish that, we ought to recognize and assess cancer as pathology and as a gadget. This calls for information the populace- and chance-based totally associations with most cancers (conduct, socioeconomic factors, and epidemiology) and the fundamental mechanisms of tumor genesis (genetics, epigenetics, signaling, tumor microenvironment, and immune elements), and integrating this know-how in a tangible manner. Although the sector of oncology has stepped forward extensively in precision medicine initiatives in diagnosis and remedy, cancer screening and prevention has no longer stuck up to those advances. Nonetheless, most cancers prevention and early detection should, and perhaps need to, adapt the techniques that are now common in precision medicinal drug to precision prevention tasks. The use of most cancers immunoprevention and immunotherapy has already begun moving within the precision prevention direction.


  1. Miller ABThe future of cancer prevention. Prev Med. 2012;55(6):554-5.
  2. Indexed at, Google Scholar, Cross Ref

  3. Miller SM, Bowen DJ, Lyle J, et al. Primary prevention, aging, and cancer: overview and future perspectives. Cancer: Interdisciplinary. Int J Am Cancer Soc. 2008;113(S12):3484-92.
  4. Indexed at, Google Scholar, Cross Ref

  5. Tamborero Noguera D, Gonzalez-Perez A, Pérez Llamas C, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013; 3: 2650. 2013.
  6. Indexed at, Google Scholar, Cross Ref

  7. Rebbeck TR. Precision prevention of cancer. Cancer Epidemiol Prev Biomarkers. 2014;23(12):2713-5.
  8. Indexed at, Google Scholar, Cross Ref

  9. Deng X, Nakamura Y. Cancer precision medicine: from cancer screening to drug selection and personalized immunotherapy. Trends Pharmacol Sci. 2017;38(1):15-24.
  10. Indexed at, Google Scholar, Cross Ref

Get the App